IRulya Therapeutics, Inc. (IRLA)
32.95
+1.33
(+4.21%)
USD |
NASDAQ |
Oct 30, 16:00
33.50
+0.55
(+1.67%)
After-Hours: 20:00
IRulya Therapeutics Cash from Operations (Quarterly) : -18.89M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.89M |
| March 31, 2026 | -7.627M |
| December 31, 2025 | -10.48M |
| September 30, 2025 | -9.928M |
| June 30, 2025 | -11.42M |
| March 31, 2025 | -9.601M |
| December 31, 2024 | -7.552M |
| September 30, 2024 | -7.26M |
| June 30, 2024 | -8.739M |
| March 31, 2024 | -8.353M |
| December 31, 2023 | -6.078M |
| September 30, 2023 | -4.818M |
| June 30, 2023 | -3.827M |
| March 31, 2023 | -3.569M |
| December 31, 2022 | -5.835M |
| September 30, 2022 | -6.697M |
| June 30, 2022 | -15.42M |
| Date | Value |
|---|---|
| March 31, 2022 | -16.09M |
| December 31, 2021 | -14.42M |
| September 30, 2021 | -17.34M |
| June 30, 2021 | -17.56M |
| March 31, 2021 | -13.61M |
| December 31, 2020 | -13.28M |
| September 30, 2020 | -12.37M |
| June 30, 2020 | -14.39M |
| March 31, 2020 | -10.78M |
| December 31, 2019 | -10.95M |
| September 30, 2019 | -8.796M |
| June 30, 2019 | -6.315M |
| March 31, 2019 | -7.216M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | -2.62M |
| March 31, 2018 | -3.177M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -1.432M |
| PepGen Inc. | -15.81M |
| Q32 Bio, Inc. | -3.075M |
| Bridgebio Oncology Therapeutics, Inc. | -44.36M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 8.001M |
| Cash from Financing (Quarterly) | 108.93M |
| Free Cash Flow | -47.00M |
| Free Cash Flow Per Share (Quarterly) | -3.080 |
| Free Cash Flow to Equity (Quarterly) | -18.48M |
| Free Cash Flow to Firm (Quarterly) | -18.89M |
| Free Cash Flow Yield | -79.90% |